Illumina Ventures

Investor type Corporate Venture Capital
Founders Nicholas J. Naclerio

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 51
Average round size
info
The average size of a deal this fund participated in
$49M
Portfolio companies 28
Rounds per year 8.50
Lead investments 11
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.45
Exits 2
Key employees 4

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Life Science
  • Genetics
Summary

Illumina Ventures is the famous VC, which was founded in 2016. The company was established in North America in United States. Illumina Ventures appeared to be a CVC structure as part of the corporation. The main department of described VC is located in the Foster City.

Among the most popular portfolio startups of the fund, we may highlight 23andMe, Human Longevity, DNA Script. The fund has no exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Health Diagnostics, Genetics. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.

This organization was formed by Nicholas J. Naclerio. The overall number of key employees were 4.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Illumina Ventures, startups are often financed by Polaris Partners, NanoDimension, Alexandria Venture Investments. The meaningful sponsors for the fund in investment in the same round are Polaris Partners, Alexandria Venture Investments, ARCH Venture Partners. In the next rounds fund is usually obtained by Euclidean Capital, Bpifrance, Two Sigma Ventures.

Comparing to the other companies, this Illumina Ventures performs on 23 percentage points less the average number of lead investments. The higher amount of exits for fund were in 2018. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. Speaking about the real fund results, this VC is 24 percentage points more often commits exit comparing to other organizations. The average startup value when the investment from Illumina Ventures is 500 millions - 1 billion dollars. The fund is constantly included in 2-6 deals per year. Deals in the range of 10 - 50 millions dollars are the general things for fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Illumina Ventures:
Typical Co-investors
Illumina Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Illumina Ventures:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AMD Ventures California, Sunnyvale, United States
Clinton Group New York, New York, United States
Dt&Investment -
Kompas Gramedia Indonesia, Jakarta, Jakarta Raya
Lenovo Capital and Incubator Group (LCIG) Beijing, Beijing, China
MagnaSci Ventures -
PTV Healthcare Capital Austin, Texas, United States
Qianshi Capital Beijing, Beijing, China
Schon Family Trust -
Socratic Labs New York, New York, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Sherlock Biosciences

Biotechnology
Health Care
Health Diagnostics
Life Science
$80M08 Mar 2022 Cambridge, Massachusetts, United States

Kallyope

Biotechnology
Health Care
Medical
Pharmaceutical
$236M15 Feb 2022 New York, New York, United States

Stilla Technologies

Biotechnology
Genetics
$36M23 Nov 2021 France, Ile-de-France, France

DNA Script

Biotechnology
Health Care
Life Science
Medical
$165M26 Oct 2021 France, Ile-de-France, France

RedShift BioAnalytics

Biotechnology
Electronics
Enterprise Software
Manufacturing
$20M18 Oct 2021 Massachusetts, United States

Walking Fish Therapeutics

Biotechnology
Life Science
$50M13 Sep 2021 San Francisco, California, United States

Alamar Biosciences

Biotechnology
Health Care
Medical
$80M08 Sep 2021 Hayward, California, United States

Genome Medical

Genetics
Health Care
Life Science
Medical
$60M30 Aug 2021 South San Francisco, California, United States

NanoCellect Biomedical

Biotechnology
Hardware
Health Care
Health Diagnostics
Medical Device
$20M13 Aug 2021 San Diego, California, United States
News
Walking Fish Therapeutics Launches with $50 Million in Series A Financing to Accelerate Development of B Cell Therapies for Multiple Diseases

– Walking Fish Therapeutics, a leader in B cell engineering, announced the close of $50M Series A financing— led by Emerson Collective, Illumina Ventures and Quan Capital— to develop B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production.
– Walking Fish Therapeutics has made critical advances in developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies.

LetsGetChecked Announces $150 Million Series D Fundraise to Grow Comprehensive Virtual Care Capabilities

– LetsGetChecked announced the completion of a $150m Series D round of financing.
– The funding was led by Casdin Capital with continued participation from CommonFund Capital, Illumina Ventures, Optum Ventures, Transformation Capital, HLM Venture Partners, Qiming Venture Partners USA, and professional golfer Rory Mcllroy through Symphony Ventures, an investment partnership.
– This latest financing brings the total capital raised by LetsGetChecked to more than $260m.
– LetsGetChecked will use the new capital to launch care pathways, a 360-degree customer care journey that will provide remote care for patients with ailments and chronic conditions.
– Care pathways is enabled by LetsGetChecked’s core offerings, including telehealth services, pharmacy capabilities, and at-home diagnostics.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Illumina Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: